Literature DB >> 33363036

Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma.

Jie Qian1, Rongrong Chen2, Ruiying Zhao3, Yuchen Han3, Yongfeng Yu1.   

Abstract

BACKGROUND: This study aims to profile integrative genomic spectra of Chinese patients with different subtypes of lung squamous cell carcinoma (LUSC) and explore potential molecular prognosis factors.
METHODS: We retrospectively identified 204 surgically resected LUSC patients in Shanghai Chest Hospital who underwent capture-based targeted next-generation sequencing (NGS) with a panel of 68 lung cancer-related genes from September 2017 to January 2019. NGS was used to profile comprehensive molecular characterizations.
RESULTS: Of 204 cases, 114 (55.9%) were keratinizing squamous cell carcinoma (KSCC), 77 (37.7%) were non-keratinizing squamous cell carcinoma (NKSCC), 13 (6.4%) were basaloid squamous cell carcinoma (BSCC), respectively. All subtypes presented similarly high proportions of mutations, including TP53, CDKN2A, and NOTCH1. A comparable prevalence of FGFR1 amplifications was identified between KSCC and NKSCC (11.4 versus 26.9%, p = 0.007). Compared with NKSCC, IGF1R amplifications were more frequent in BSCC (0 versus 15.4%, p = 0.019). We found cases with TP53 alterations had less EGFR alterations in KSCC (P = 0.013, OR = 0.158). Compared with TCGA cohorts, our Chinese cohorts exhibited statistic differences in both somatic mutations and signaling pathways. We found that STK 11 alterations and TOP2A alterations were significantly associated with higher risk of recurrence in patients with LUSC.
CONCLUSIONS: Significant differences exist among three subtypes of LUSC in molecular characterizations.
Copyright © 2020 Qian, Chen, Zhao, Han and Yu.

Entities:  

Keywords:  genetic profiles; histopathological subtypes; lung squamous cell carcinoma; next-generation sequencing; prognosis factors

Year:  2020        PMID: 33363036      PMCID: PMC7758445          DOI: 10.3389/fonc.2020.607130

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  35 in total

1.  LKB1 modulates lung cancer differentiation and metastasis.

Authors:  Hongbin Ji; Matthew R Ramsey; D Neil Hayes; Cheng Fan; Kate McNamara; Piotr Kozlowski; Chad Torrice; Michael C Wu; Takeshi Shimamura; Samanthi A Perera; Mei-Chih Liang; Dongpo Cai; George N Naumov; Lei Bao; Cristina M Contreras; Danan Li; Liang Chen; Janakiraman Krishnamurthy; Jussi Koivunen; Lucian R Chirieac; Robert F Padera; Roderick T Bronson; Neal I Lindeman; David C Christiani; Xihong Lin; Geoffrey I Shapiro; Pasi A Jänne; Bruce E Johnson; Matthew Meyerson; David J Kwiatkowski; Diego H Castrillon; Nabeel Bardeesy; Norman E Sharpless; Kwok-Kin Wong
Journal:  Nature       Date:  2007-08-05       Impact factor: 49.962

2.  Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Erin Bange; Melina E Marmarelis; Wei-Ting Hwang; Yu-Xiao Yang; Jeffrey C Thompson; Jason Rosenbaum; Joshua M Bauml; Christine Ciunci; Evan W Alley; Roger B Cohen; Corey J Langer; Erica Carpenter; Charu Aggarwal
Journal:  JCO Precis Oncol       Date:  2019-05-10

3.  FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution.

Authors:  Aaron M Newman; Scott V Bratman; Henning Stehr; Luke J Lee; Chih Long Liu; Maximilian Diehn; Ash A Alizadeh
Journal:  Bioinformatics       Date:  2014-08-20       Impact factor: 6.937

Review 4.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

5.  Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics.

Authors:  Wei Guo; Sijin Sun; Lei Guo; Peng Song; Xuemin Xue; Hao Zhang; Guochao Zhang; Zhen Wang; Bin Qiu; Fengwei Tan; Qi Xue; Yibo Gao; Shugeng Gao; Jie He
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-26       Impact factor: 4.553

6.  Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity.

Authors:  Christian Brambilla; Julien Laffaire; Sylvie Lantuejoul; Denis Moro-Sibilot; Hélène Mignotte; François Arbib; Anne-Claire Toffart; Fabien Petel; Pierre Hainaut; Sophie Rousseaux; Saadi Khochbin; Aurélien de Reyniès; Elisabeth Brambilla
Journal:  Clin Cancer Res       Date:  2014-09-04       Impact factor: 12.531

7.  Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.

Authors:  Susanne Horn; Sonia Leonardelli; Antje Sucker; Dirk Schadendorf; Klaus G Griewank; Annette Paschen
Journal:  J Natl Cancer Inst       Date:  2018-06-01       Impact factor: 13.506

8.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

9.  Mutational signatures associated with tobacco smoking in human cancer.

Authors:  Ludmil B Alexandrov; Young Seok Ju; Kerstin Haase; Peter Van Loo; Iñigo Martincorena; Serena Nik-Zainal; Yasushi Totoki; Akihiro Fujimoto; Hidewaki Nakagawa; Tatsuhiro Shibata; Peter J Campbell; Paolo Vineis; David H Phillips; Michael R Stratton
Journal:  Science       Date:  2016-11-04       Impact factor: 47.728

10.  Genetic alteration profiling of patients with resected squamous cell lung carcinomas.

Authors:  Dan Tao; Xiaohong Han; Ningning Zhang; Dongmei Lin; Di Wu; Xinxin Zhu; Wenya Song; Yuankai Shi
Journal:  Oncotarget       Date:  2016-06-14
View more
  5 in total

Review 1.  Use of cucurbitacins for lung cancer research and therapy.

Authors:  Min Liu; Qijia Yan; Bi Peng; Yuan Cai; Shuangshuang Zeng; Zhijie Xu; Yuanliang Yan; Zhicheng Gong
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-06       Impact factor: 3.333

2.  A novel anti-lung cancer agent inhibits proliferation and epithelial-mesenchymal transition.

Authors:  Wen Zhao; Ye Xu; Qingkui Guo; Wenliang Qian; Chen Zhu; Min Zheng
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.573

3.  Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.

Authors:  Xiaoqian Zhai; Qiang Wu; Dan Pu; Liyuan Yin; Weiya Wang; Daxing Zhu; Feng Xu
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

4.  Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations.

Authors:  Giuseppe Pelosi; Matteo Bulloni; Martina Vescio; Silvia Uccella; Fabien Forest; Giorgia Leone; Massimo Barberis; Daoud Rahal; Paola Bossi; Giovanna Finzi; Deborah Marchiori; Marco De Luca; Fausto Sessa; Sergio Harari; Manuela Spinelli; Patrizia Viola; Paolo Macrì; Stefania Maria; Antonio Rizzo; Antonio Picone; Linda Pattini
Journal:  JTO Clin Res Rep       Date:  2021-09-02

5.  EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes.

Authors:  Rui Jin; Ling Peng; Jiawei Shou; Jin Wang; Yin Jin; Fei Liang; Jing Zhao; Mengmeng Wu; Qin Li; Bin Zhang; Xiaoying Wu; Fen Lan; Lixia Xia; Junrong Yan; Yang Shao; Justin Stebbing; Huahao Shen; Wen Li; Yang Xia
Journal:  Front Oncol       Date:  2021-06-14       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.